No Data
No Data
Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating
Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Buy Rating Affirmed: Aprea Therapeutics Poised for Growth With Strong Pipeline Momentum Into 2024
Express News | HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Maintains $20 Price Target
No Data
hard-working Camel_4 : going to fly once market open
TrytosaveabitOP hard-working Camel_4: I don’t believe! This PR is just a update from a couple days ago with exception of the PP is closed im thinking